Duration of protection against Bordetella pertussis infection elicited by whole-cell and acellular vaccine priming in Polish children and adolescents

被引:3
|
作者
Paradowska-Stankiewicz, Iwona [1 ]
Rumik, Agnieszka [1 ]
Bogusz, Joanna [1 ]
Zbrzezniak, Jakub [1 ]
Rastawicki, Waldemar [1 ]
Smietanska, Karolina [1 ]
Vargas-Zambrano, Juan C. [2 ]
Macina, Denis [2 ]
机构
[1] Natl Inst Publ Hlth, Natl Inst Hyg, Natl Res Inst, Ul Chocimska 24, PL-00791 Warsaw, Poland
[2] Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, France
关键词
Pertussis; Vaccines; Seroprevalence; Waning; REDUCED RISK; IMMUNITY; RECIPIENTS; DURABILITY; EXEMPTIONS; CALIFORNIA; DISEASE;
D O I
10.1016/j.vaccine.2021.08.105
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: In the context of reported resurgence of pertussis in the last decade, researchers hypothesized that acellular (aP) pertussis vaccines elicit a shorter-lived protection compared to whole-cell (wP) pertussis vaccines. However, in the studies seeking to demonstrate this hypothesis, exposure to each vaccine type was not concurrent, and contradictory epidemiologic modeling questioned its validity. The context of pertussis vaccination history in Poland, with both vaccine types used concurrently in comparable proportions, provided an opportunity to investigate this hypothesis. We sought to compare waning of protection by primary series vaccine type by measuring anti-pertussis toxin antibody concentrations as proxy for recent infection. Materials and methods: Serological samples from 2,745 children and adolescents aged >5 years and <16 years and with completed 5-dose pertussis vaccination series were tested by ELISA for pertussis toxin (PT) antibodies. Participants were stratified by type of priming vaccine (wP or aP). Vaccination timeliness and priming-specific trends in anti-PT antibody levels by time since last vaccine dose were analyzed. Results: A total of 1,161 (42.5%) children received wP vaccines, and 1,314 (48.1%) received aP vaccines for their primary series and toddler booster. Overall, 53.57% of the subjects received doses 2-4 in a timely manner, while only 41.52% received all 5 doses at the recommended intervals. Using GMCs or seropositivity measures, both priming groups showed a re-increase in anti-PT antibody levels signing infection in recent years from 8 years after the school-entry booster onward. Comparisons did not show any significant differences between the two groups in the timing or intensity of this re-increase. Conclusion: Our results clearly confirm that vaccine-elicited immunity against pertussis wanes among adolescents even after a complete infant, toddler and school-entry vaccination series. The timing and intensity of the waning of protection appear similar with whole-cell as with acellular pertussis vaccines. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:6067 / 6073
页数:7
相关论文
共 50 条
  • [41] Bordetella pertussis population changes under whole-cell and acellular pertussis vaccines-induced immunity selection pressure in Poland
    Maciej Polak
    Ewa Mosiej
    Marta Prygiel
    Aleksandra A. Zasada
    European Journal of Clinical Microbiology & Infectious Diseases, 2022, 41 : 1283 - 1284
  • [42] Bordetella pertussis population changes under whole-cell and acellular pertussis vaccines-induced immunity selection pressure in Poland
    Polak, Maciej
    Mosiej, Ewa
    Prygiel, Marta
    Zasada, Aleksandra A.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2022, 41 (10) : 1283 - 1284
  • [43] The efficacy of a whole cell pertussis vaccine and fimbriae against Bordetella pertussis and Bordetella parapertussis infections in respiratory mouse model
    Heininger, U
    Stehr, K
    Cherry, JD
    VACCINE, 1998, 16 (13) : 1255 - 1255
  • [44] The efficacy of a whole cell pertussis vaccine and fimbriae against Bordetella pertussis and Bordetella parapertussis infections in a respiratory mouse model
    Willems, RJL
    Kamerbeek, J
    Geuijen, CAW
    Top, J
    Gielen, H
    Gaastra, W
    Mooi, FR
    VACCINE, 1998, 16 (04) : 410 - 416
  • [45] ISOTYPE AND ANTIGEN-SPECIFICITY OF PERTUSSIS AGGLUTININS FOLLOWING WHOLE-CELL PERTUSSIS VACCINATION AND INFECTION WITH BORDETELLA-PERTUSSIS
    MINK, CM
    OBRIEN, CH
    WASSILAK, S
    DEFOREST, A
    MEADE, BD
    INFECTION AND IMMUNITY, 1994, 62 (03) : 1118 - 1120
  • [46] BOOSTER RESPONSE TO ACELLULAR PERTUSSIS-VACCINE IN CHILDREN PRIMED WITH ACELLULAR OR WHOLE CELL VACCINES
    EDWARDS, KM
    DECKER, MD
    BRADLEY, RB
    TAYLOR, JC
    HAGER, CC
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1991, 10 (04) : 315 - 318
  • [47] Prevalence and characterization of pertactin deficient Bordetella pertussis strains in Brazil, a whole-cell vaccine country
    Leite, Daniela
    Camargo, Carlos Henrique
    Kashino, Suely Sanae
    Polatto, Ricardo
    Martins, Luciano Moura
    Pereira, Juliana Cristina
    Pawloski, Lucia
    Tondella, Maria Lucia
    de Oliveira, Rosangela Siqueira
    de Lima, Lourdes Rehder de Andrade Vaz
    VACCINE: X, 2021, 8
  • [48] Whole-cell pertussis vaccine in early infancy for the prevention of allergy in children
    Chacon, Gladymar Perez
    Ramsay, Jessica
    Brennan-Jones, Christopher G.
    Estcourt, Marie J.
    Richmond, Peter
    Holt, Patrick
    Snelling, Tom
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (09):
  • [49] Nitric oxide induction in murine macrophages and spleen cells by whole-cell Bordetella pertussis vaccine
    Xing, DKL
    Canthaboo, C
    Corbel, MJ
    VACCINE, 1998, 16 (01) : 16 - 23
  • [50] Aggravated lung pathology and induction of immediate hypersensitivity in mice by a whole-cell and an acellular pertussis vaccine
    Vandebriel, R
    Vermeulen, J
    van Hartskamp, M
    Hellwig, S
    Dormans, J
    Roholl, P
    FASEB JOURNAL, 2003, 17 (07): : C22 - C22